Core Insights - Medline shares experienced a significant increase of nearly 25% during their trading debut, with the stock priced around $36 after an IPO that raised $6.26 billion, marking one of the largest IPOs in recent years [1][4][7] Company Overview - Medline sold over 216 million shares at $29 each, at the higher end of its anticipated range of $26 to $30, with plans to use the proceeds to reduce debt [2][4] - The company offers over 335,000 medical and surgical products, including protective equipment and testing kits, and has reported consistent annual sales growth since its inception [2] Financial Performance - For the first nine months of the year ending September, Medline reported a net income of $977 million on revenues of $20.65 billion, an increase from a net income of $911 million on $18.72 billion in revenue during the same period the previous year [3] Market Context - The IPO marks a recovery in the IPO market, although overall activity remains below the record levels seen in 2021; Medline's IPO is the largest since Rivian's $11.93 billion IPO in 2021 [4][7] Strategic Vision - CEO Jim Boyle expressed that the IPO is expected to enhance Medline's brand, positioning the company as the "Costco of healthcare" for its medical equipment customers, leveraging its private label products and strong supply chain [5]